Martino E, Pinchera A, Capiferri R, Macchia E, Sardano G, Bartalena L, Mazzanti F, Baschieri L
J Clin Endocrinol Metab. 1976 Sep;43(3):543-9. doi: 10.1210/jcem-43-3-543.
Responsiveness to synthetic thyrotropin-releasing hormone (TRH), thyroid suppressibility by triiodothyronine (T3) and the outcome of hyperthyroidism following prolonged therapy with thionamides were studied in a group of 35 patients with toxic diffuse goiter. TRH and T3 suppression tests were performed 10 days to 24 months (mean 4 months) after withdrawal of antithyroid drugs. Nineteen patients were euthyroid and had a normal thyrotropin (TSH) response to TRH, while 4 were recovering from mild hypothyroidism due to overtreatment and had an exaggerated response. No response was observed in 12 patients with recurrent hyperthyroidism. Positive T3 suppression tests were found only in 10 of the 30 cases examined. Peak and net 2 h secretion responses of TSH to TRH exhibited a significant inverse correlation with the levels of serum thyroxine and serum triiodothyronine, but were unrelated to the degree of thyroid suppressibility. Relapse or recurrence of thyrotoxicosis occurred in at least 9 of the 23 patients having no evidence of hyperthyroidism at the time of TRH test. Each of them was found to be responsive to TRH, while the T3 suppression test was negative in 8 and had to be discontinued in one because of thyrotoxic symptoms. The present data indicate that during the early period after completion of a prolonged course of antithyroid drug therapy responsiveness to TRH in toxic diffuse goiter is: a) correlated with circulating thyroid hormones, b) unrelated to the degree of thyroid suppressibility by T3 and c) of little value in predicting the long-term results of treatment.
对35例毒性弥漫性甲状腺肿患者进行了研究,观察其对合成促甲状腺激素释放激素(TRH)的反应性、三碘甲状腺原氨酸(T3)对甲状腺的抑制作用以及硫代酰胺类药物长期治疗后甲状腺功能亢进症的转归。在停用抗甲状腺药物后10天至24个月(平均4个月)进行TRH和T3抑制试验。19例患者甲状腺功能正常,对TRH的促甲状腺激素(TSH)反应正常,4例因治疗过度正从轻度甲状腺功能减退中恢复,其反应过度。12例复发性甲状腺功能亢进患者未观察到反应。在所检查的30例中,仅10例T3抑制试验阳性。TSH对TRH的2小时分泌峰值和净反应与血清甲状腺素和血清三碘甲状腺原氨酸水平呈显著负相关,但与甲状腺抑制程度无关。在TRH试验时无甲状腺功能亢进证据的23例患者中,至少9例发生甲状腺毒症复发或再发。他们每个人对TRH均有反应,而8例T3抑制试验阴性,1例因甲状腺毒症症状不得不中断试验。目前的数据表明,在长期抗甲状腺药物治疗结束后的早期,毒性弥漫性甲状腺肿对TRH的反应性:a)与循环甲状腺激素相关;b)与T3对甲状腺的抑制程度无关;c)对预测治疗的长期结果价值不大。